ɑ-Synuclein strains and the variable pathologies of synucleinopathies

Journal of Neurochemistry

Volumn 139, Issue , 2016, Pages 256-274

  Peelaerts, Wouter ^a   Baekelandt, Veerle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

alpha synuclein; Parkinson's disease; prion; synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN;

AGING; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; GENE IDENTIFICATION; GENE PRODUCT; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MISFOLDING; REVIEW; SHY DRAGER SYNDROME; SNCA GENE; WESTERN BLOTTING; ANIMAL; DEGENERATIVE DISEASE; DEMENTIA; GENETIC VARIATION; GENETICS; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; DEMENTIA; GENETIC VARIATION; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84963594931     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13595     Document Type: Review

References (199)

1. Aasly J. O. et al. (2014) Elevated levels of cerebrospinal fluid alpha-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers. Front. Aging Neurosci. 6, 248. doi:10.3389/fnagi.2014.00248.
2. Aguzzi A., Heikenwalder M. and Polymenidou M. (2007) Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8, 552–561. doi:nrm2204 [pii]10.1038/nrm2204.
3. Asi Y. T. et al. (2014) Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62, 964–970. doi:10.1002/glia.22653.
4. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865–868. doi:10.1126/science.1067389.
5. Ayers J. I., Schutt C. R., Shikiya R. A., Aguzzi A., Kincaid A. E. & Bartz J. C. (2011) The Strain-Encoded Relationship between PrPSc Replication, Stability and Processing in Neurons is Predictive of the Incubation Period of Disease. (N. A. Mabbott, Ed.) PLoS Pathog. 7(3), e1001317. doi:10.1371/journal.ppat.1001317.s008.
6. Baldwin A. J. et al. (2011) Metastability of native proteins and the phenomenon of amyloid formation. J. Am. Chem. Soc. 133, 14160–14163. doi:10.1021/ja2017703.
7. Bandyopadhyay U. and Cuervo A. M. (2007) Chaperone-mediated autophagy in aging and neurodegeneration: lessons from alpha-synuclein. Exp. Gerontol. 42, 120–128. doi:10.1016/j.exger.2006.05.019.
8. Beilina A. et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci. USA 111, 2626–2631. doi:10.1073/pnas.1318306111.
9. Bendor J. T., Logan T. P. and Edwards R. H. (2013) The function of alpha-synuclein. Neuron 79, 1044–1066. doi:10.1016/j.neuron.2013.09.004.
10. Berg D. et al. (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov. Disord. 29, 454–462. doi:10.1002/mds.25844.
11. Bessen R. A. and Marsh R. F. (1992) Biochemical and physical-properties of the prion protein from 2 strains of the transmissible mink encephalopathy agent. J. Virol. 66, 2096–2101.
12. Bloch A., Probst A., Bissig H., Adams H. and Tolnay M. (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol. Appl. Neurobiol. 32, 284–295. doi:10.1111/j.1365-2990.2006.00727.x.
13. Bolognesi B. et al. (2010) ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 5, 735–740. doi:10.1021/cb1001203.
14. Borbat P., Ramlall T. F., Freed J. H. and Eliezer D. (2006) Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J. Am. Chem. Soc. 128, 10004–10005. doi:10.1021/ja063122l.
15. Bousset L. et al. (2013) Structural and functional characterization of two alpha-synuclein strains. Nat. Commun. 4, 2575. doi:ncomms3575 [pii]10.1038/ncomms3575.
16. Braak H. and Del Tredici K. (2008) Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916–1925. doi:70/20/1916 [pii]10.1212/01.wnl.0000312279.49272.9f.
17. Braak H. and Del Tredici K. (2009) Neuroanatomy and pathology of sporadic Parkinson's disease. Adv. Anat. Embryol. Cell Biol. 201, 1–119.
18. Braak H. et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211. doi:S0197458002000659 [pii].
19. Breydo L., Wu J. W. and Uversky V. N. (1822) Alpha-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 261–285, 2012. doi:10.1016/j.bbadis.2011.10.002.
20. Bruinsma I. B. et al. (2011) Inhibition of alpha-synuclein aggregation by small heat shock proteins. Proteins 79, 2956–2967. doi:10.1002/prot.23152.
21. Buell A. K. et al. (2014) Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation. Proc. Natl Acad. Sci. USA 111, 7671–7676. doi:10.1073/pnas.1315346111.
22. Burre J., Sharma M. and Sudhof T. C. (2014) Alpha-synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc. Natl Acad. Sci. USA 111, E4274–E4283. doi:10.1073/pnas.1416598111.
23. Bussell R., Jr, Ramlall T. F. and Eliezer D. (2005) Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci. 14, 862–872. doi:10.1110/ps.041255905.
24. Campbell B. C. et al. (2001) The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J. Neurochem. 76, 87–96.
25. Chartier-Harlin M. C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167–1169. doi:S0140-6736(04)17103-1 [pii]10.1016/S0140-6736(04)17103-1.
26. Chen S. W. et al. (2015) Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation. Proc. Natl Acad. Sci. USA 112, E1994–E2003. doi:10.1073/pnas.1421204112.
27. Chiti F. and Dobson C. M. (2006) Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75, 333–366. doi:10.1146/annurev.biochem.75.101304.123901.
28. Chu Y., Dodiya H., Aebischer P., Olanow C. W. and Kordower J. H. (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 35, 385–398. doi:10.1016/j.nbd.2009.05.023.
29. Clayton D. F. and George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120–129.
30. Cohlberg J. A., Li J., Uversky V. N. and Fink A. L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41, 1502–1511.
31. Collinge J. and Clarke A. R. (2007) A general model of prion strains and their pathogenicity. Science 318, 930–936. doi:10.1126/science.1138718.
32. Collinge J., Sidle K. C. L., Meads J., Ironside J. and Hill A. F. (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383, 685–690. doi:10.1038/383685a0.
33. Cremades N. et al. (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149, 1048–1059. doi:10.1016/j.cell.2012.03.037.
34. Croisier E. et al. (2006) Comparative study of commercially available anti-alpha-synuclein antibodies. Neuropathol. Appl. Neurobiol. 32, 351–356. doi:10.1111/j.1365-2990.2006.00722.x.
35. Crowther R. A., Daniel S. E. and Goedert M. (2000) Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain. Neurosci. Lett. 292, 128–130.
36. Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292–1295. doi:10.1126/science.1101738.
37. Cykowski M. D. et al. (2015) Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 138, 2293–2309. doi:10.1093/brain/awv114.
38. De Rijk M. C., Tzourio C., Breteler M. M., Dartigues J. F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J. M., Alperovitch A. and Rocca W. A., for the EUROPARKINSON & Group, S. (1994) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. J. Neurosurg. 1997; 62: 10–15.
39. Dearborn A. D. et al. (2015) Alpha-synuclein amyloid fibrils with two entwined, asymmetrically associated, protofibrils. J. Biol. Chem. doi:10.1074/jbc.M115.698787.
40. Dearmond S. J. et al. (1985) Identification of prion amyloid filaments in scrapie-infected brain. Cell 41, 221–235. doi:10.1016/0092-8674(85)90076-5.
41. Dedmon M. M., Christodoulou J., Wilson M. R. and Dobson C. M. (2005) Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J. Biol. Chem. 280, 14733–14740. doi:10.1074/jbc.M413024200.
42. Del Tredici K. and Braak H. (2012) Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 124, 643–664. doi:10.1007/s00401-012-1028-y.
43. Desplats P. et al. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015. doi:10.1073/pnas.0903691106.
44. Dettmer U., Newman A. J., Luth E. S., Bartels T. and Selkoe D. (2013) In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J. Biol. Chem. 288, 6371–6385. doi:10.1074/jbc.M112.403311.
45. Dettmer U., Newman A. J., von Saucken V. E., Bartels T. and Selkoe D. (2015a) KTKEGV repeat motifs are key mediators of normal alpha-synuclein tetramerization: their mutation causes excess monomers and neurotoxicity. Proc. Natl Acad. Sci. USA 112, 9596–9601. doi:10.1073/pnas.1505953112.
46. Dettmer U. et al. (2015b) Parkinson-causing alpha-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation. Nat. Commun. 6, 7314. doi:10.1038/ncomms8314.
47. Dhungel N. et al. (2015) Parkinson's disease genes VPS35 and EIF4G1 interact genetically and converge on alpha-synuclein. Neuron 85, 76–87. doi:10.1016/j.neuron.2014.11.027.
48. Dickson D. W. et al. (1999) Widespread alterations of alpha-synuclein in multiple system atrophy. Am. J. Pathol. 155, 1241–1251.
49. Djelloul M. et al. (2015) Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports 5, 174–184. doi:10.1016/j.stemcr.2015.07.002.
50. Dobson C. M. (2001) The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. B 356, 133–145. doi:10.1098/Rstb.2000.0758.
51. Duda J. E. et al. (2000) Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J. Neuropathol. Exp. Neurol. 59, 830–841.
52. Ebrahimi-Fakhari D. et al. (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J. Neurosci. 31, 14508–14520. doi:10.1523/JNEUROSCI.1560-11.2011.
53. El-Agnaf O. M. et al. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419–425. doi:20/3/419 [pii]10.1096/fj.03-1449com.
54. Emmanouilidou E. et al. (2010) Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci. 30, 6838–6851. doi:10.1523/JNEUROSCI.5699-09.2010.
55. Fanciulli A. and Wenning G. K. (2015) Multiple-system atrophy. N. Engl. J. Med. 372, 249–263. doi:10.1056/NEJMra1311488.
56. Fandrich M. and Dobson C. M. (2002) The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21, 5682–5690. doi:10.1093/Emboj/Cdf573.
57. Ferguson M. C. et al. (2014) SHC2 gene copy number in multiple system atrophy (MSA). Clin. Auton. Res. 24, 25–30. doi:10.1007/s10286-013-0216-8.
58. Ferreon A. C., Gambin Y., Lemke E. A. and Deniz A. A. (2009) Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc. Natl Acad. Sci. USA 106, 5645–5650. doi:10.1073/pnas.0809232106.
59. Fraser H. and Dickinso A. G. (1973) Scrapie in mice - agent-strain differences in distribution and intensity of grey matter vacuolation. J. Comp. Pathol. 83, 29–40. doi:10.1016/0021-9975(73)90024-8.
60. Fusco G. et al. (2014) Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. Nat. Commun. 5, 3827. doi:10.1038/ncomms4827.
61. Galvagnion C. et al. (2015) Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol. 11, 229–234. doi:10.1038/nchembio.1750.
62. Gao X. et al. (2015) Human Hsp70 disaggregase reverses Parkinson's-linked alpha-synuclein amyloid fibrils. Mol. Cell 59, 781–793. doi:10.1016/j.molcel.2015.07.012.
63. Georgieva E. R., Ramlall T. F., Borbat P. P., Freed J. H. and Eliezer D. (2010) The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between the broken and extended helix forms. J. Biol. Chem. 285, 28261–28274. doi:10.1074/jbc.M110.157214.
64. Giasson B. I., Uryu K., Trojanowski J. Q. and Lee V. M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619–7622.
65. Gilman S. et al. (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676. doi:10.1212/01.wnl.0000324625.00404.15.
66. Goedert M. (2001) Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492–501. doi:10.1038/3508156435081564 [pii].
67. Goedert M., Spillantini M. G., Del Tredici K. and Braak H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13–24. doi:10.1038/nrneurol.2012.242.
68. Goldfarb L. G. et al. (1992) Fatal familial insomnia and familial Creutzfeldt-Jakob disease - disease phenotype determined by a DNA polymorphism. Science 258, 806–808. doi:10.1126/Science.1439789.
69. Gomez-Tortosa E. et al. (1999) Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 53, 1284–1291.
70. Guo J. L. et al. (2013) Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154, 103–117. doi:S0092-8674(13)00700-9 [pii]10.1016/j.cell.2013.05.057.
71. Halliday G., Hely M., Reid W. and Morris J. (2008) The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol. 115, 409–415. doi:10.1007/s00401-008-0344-8.
72. Hansen C. et al. (2011) Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715–725. doi:10.1172/JCI4336643366 [pii].
73. Hansson O. et al. (2014) Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res. Ther. 6, 25. doi:10.1186/alzrt255.
74. Hartl F. U., Bracher A. and Hayer-Hartl M. (2011) Molecular chaperones in protein folding and proteostasis. Nature 475, 324–332. doi:10.1038/nature10317.
75. Heise H. et al. (2005) Molecular-level secondary structure, polymorphism, and dynamics of full-length alpha-synuclein fibrils studied by solid-state NMR. Proc. Natl Acad. Sci. USA 102, 15871–15876. doi:10.1073/pnas.0506109102.
76. Hellstrand E., Nowacka A., Topgaard D., Linse S. and Sparr E. (2013) Membrane lipid co-aggregation with alpha-synuclein fibrils. PLoS ONE 8, e77235. doi:10.1371/journal.pone.0077235.
77. Holmes B. B. et al. (2013) Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl Acad. Sci. USA 110, E3138–E3147. doi:10.1073/pnas.1301440110.
78. Holmqvist S. et al. (2014) Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805–820. doi:10.1007/s00401-014-1343-6.
79. Huang C. et al. (2006) Heat shock protein 70 inhibits alpha-synuclein fibril formation via interactions with diverse intermediates. J. Mol. Biol. 364, 323–336. doi:10.1016/j.jmb.2006.08.062.
80. Ibanez P. et al. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169–1171. doi:S0140673604171043 [pii]10.1016/S0140-6736(04)17104-3.
81. Janezic S. et al. (2013) Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl Acad. Sci. USA 110, E4016–E4025. doi:10.1073/pnas.1309143110.
82. Jaunmuktane Z. et al. (2015) Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 525, 247–250. doi:10.1038/nature15369.
83. Johnson R. T. and Gibbs C. J., Jr (1998) Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N. Engl. J. Med. 339, 1994–2004. doi:10.1056/NEJM199812313392707.
84. Jones S. A. V. and O'Brien J. T. (2014) The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol. Med. 44, 673–683. doi:10.1017/S0033291713000494.
85. Kalia L. V., Kalia S. K., McLean P. J., Lozano A. M. and Lang A. E. (2013) Alpha-synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155–169. doi:10.1002/ana.23746.
86. Kascsak R. J. et al. (1985) Biochemical differences among scrapie-associated fibrils support the biological diversity of scrapie agents. J. Gen. Virol. 66, 1715–1722. doi:10.1099/0022-1317-66-8-1715.
87. Kiely A. P. et al. (2013) Alpha-synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol. 125, 753–769. doi:10.1007/s00401-013-1096-7.
88. King C. Y. and Diaz-Avalos R. (2004) Protein-only transmission of three yeast prion strains. Nature 428, 319–323. doi:10.1038/nature02391.
89. Klingelhoefer L. and Reichmann H. (2015) Pathogenesis of Parkinson disease-the gut-brain axis and environmental factors. Nat. Rev. Neurol. 11, 625–636. doi:10.1038/nrneurol.2015.197.
90. Klos K. J. et al. (2006) Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66, 1100–1102. doi:66/7/1100 [pii]10.1212/01.wnl.0000204179.88955.fa.
91. Knowles T. P., Vendruscolo M. and Dobson C. M. (2014) The amyloid state and its association with protein misfolding diseases. Nat. Rev. Mol. Cell Biol. 15, 384–396. doi:10.1038/nrm3810.
92. Kordower J. H., Chu Y., Hauser R. A., Freeman T. B. and Olanow C. W. (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504–506. doi:10.1038/nm1747.
93. Kramer M. L. and Schulz-Schaeffer W. J. (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J. Neurosci. 27, 1405–1410. doi:10.1523/JNEUROSCI.4564-06.2007.
94. Lee P. H. et al. (2006) The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J. Neural. Transm. 113, 1435–1439. doi:10.1007/s00702-005-0427-9.
95. Lee H. J., Suk J. E., Bae E. J. and Lee S. J. (2008) Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophs. Res. Commun. 372, 423–428. doi:10.1016/J.Bbrc.2008.05.045.
96. Lee H. J. et al. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262–9272. doi:10.1074/Jbc.M109.081125.
97. Legname G. et al. (2006) Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl Acad. Sci. USA 103, 19105–19110. doi:10.1073/pnas.0608970103.
98. Lemkau L. R. et al. (2012) Mutant protein A30P alpha-synuclein adopts wild-type fibril structure, despite slower fibrillation kinetics. J. Biol. Chem. 287, 11526–11532. doi:10.1074/jbc.M111.306902.
99. Lemkau L. R. et al. (2013) Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K. PLoS ONE 8, e49750. doi:10.1371/journal.pone.0049750.
100. Lewy F. H. (1932) Die Entstehung der Einschlußkörper und ihre Bedeutung für die systematische Einordnung der sogenannten Viruskrankheiten. Deutsche Zeitschrift für Nervenheilkunde 124, 93–110.
101. Li J. Y. et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501–503. doi:nm1746 [pii]10.1038/nm1746.
102. Lin X. et al. (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64, 807–827. doi:S0896-6273(09)00889-7 [pii]10.1016/j.neuron.2009.11.006.
103. Liu Y., Fallon L., Lashuel H. A., Liu Z. and Lansbury P. T., Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209–218.
104. Liu G., Aliaga L. and Cai H. (2012) Alpha-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol. 7, 145–153.
105. Lorenzen N. et al. (2014) The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation. J. Am. Chem. Soc. 136, 3859–3868. doi:10.1021/ja411577t.
106. Luk K. C. et al. (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051–20056. doi:10.1073/pnas.0908005106.
107. Luk K. C. et al. (2012a) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975–986. doi:jem.20112457 [pii]10.1084/jem.20112457.
108. Luk K. C. et al. (2012b) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949–953. doi:338/6109/949 [pii]10.1126/science.1227157.
109. Luth E. S., Bartels T., Dettmer U., Kim N. C. and Selkoe D. J. (2015) Purification of alpha-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. Biochemistry 54, 279–292. doi:10.1021/bi501188a.
110. MacLeod D. A. et al. (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron 77, 425–439. doi:10.1016/j.neuron.2012.11.033.
111. Mahul-Mellier A. L. et al. (2015) Fibril growth and seeding capacity play key roles in alpha-synuclein-mediated apoptotic cell death. Cell Death Differ. doi:10.1038/cdd.2015.79.
112. Mamais A. et al. (2013) Divergent alpha-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol. Dis. 58, 183–190. doi:10.1016/j.nbd.2013.05.017.
113. Masuda-Suzukake M. et al. (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128–1138. doi:awt037 [pii]10.1093/brain/awt037.
114. McGlinchey R. P. and Lee J. C. (2015) Cysteine cathepsins are essential in lysosomal degradation of alpha-synuclein. Proc. Natl Acad. Sci. USA 112, 9322–9327. doi:10.1073/pnas.1500937112.
115. McKeith I. G. (2006) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9, 417–423.
116. McKeith I. G. et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113–1124.
117. Medori R. et al. (1992) Fatal familial insomnia, a Prion disease with a mutation at Codon-178 of the prion protein gene. N. Engl. J. Med. 326, 444–449. doi:10.1056/Nejm199202133260704.
118. Milanesi L. et al. (2012) Direct three-dimensional visualization of membrane disruption by amyloid fibrils. Proc. Natl Acad. Sci. USA 109, 20455–20460. doi:10.1073/pnas.1206325109.
119. Monari L. et al. (1994) Fatal familial insomnia and familial Creutzfeldt-Jakob-disease - different prion proteins determined by a DNA polymorphism. Proc. Natl Acad. Sci. USA 91, 2839–2842. doi:10.1073/Pnas.91.7.2839.
120. Mougenot A. L. et al. (2012) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol. Aging 33, 2225–2228. doi:10.1016/j.neurobiolaging.2011.06.022.
121. Murphy K. E. et al. (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. Brain 137, 834–848. doi:10.1093/brain/awt367.
122. Nakamura K. et al. (2015) Filamentous aggregations of phosphorylated alpha-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol. Commun. 3, 29. doi:10.1186/s40478-015-0208-0.
123. Nalls M. A. et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377, 641–649. doi:S0140-6736(10)62345-8 [pii]10.1016/S0140-6736(10)62345-8.
124. Nalls M. A. et al. (2014) Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989–993. doi:10.1038/ng.3043.
125. Nam M. K. et al. (1850) A novel link between the conformations, exposure of specific epitopes, and subcellular localization of alpha-synuclein. Biochim. Biophys. Acta 2497–2505, 2015. doi:10.1016/j.bbagen.2015.09.006.
126. Nelson R. et al. (2005) Structure of the cross-beta spine of amyloid-like fibrils. Nature 435, 773–778. doi:10.1038/nature03680.
127. Nielsen S. B. et al. (2013) Wildtype and A30P mutant alpha-synuclein form different fibril structures. PLoS ONE 8, e67713. doi:10.1371/journal.pone.0067713.
128. Nillegoda N. B. et al. (2015) Crucial HSP70 co-chaperone complex unlocks metazoan protein disaggregation. Nature 524, 247–251. doi:10.1038/nature14884.
129. Okochi M. et al. (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275, 390–397.
130. Olzscha H. et al. (2011) Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67–78. doi:10.1016/j.cell.2010.11.050.
131. Osterberg V. R. et al. (2015) Progressive aggregation of alpha-synuclein and selective degeneration of lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252–1260. doi:10.1016/j.celrep.2015.01.060.
132. Outeiro T. F. et al. (2006) Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem. Biophys. Res. Commun. 351, 631–638. doi:10.1016/j.bbrc.2006.10.085.
133. Parkinson J. (2002) An essay on the shaking palsy. 1817. J. Neuropsy. Clin Neurosci. 14, 223–236; discussion 222.
134. Pasanen P. et al. (2014) Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging 35, e2181–e2185. doi:10.1016/j.neurobiolaging.2014.03.024.
135. Pattison I. H. and Millson G. C. (1961) Scrapie produced experimentally in goats with special reference to clinical syndrome. J. Comp. Pathol. Ther. 71, 101–108.
136. Peelaerts W. et al. (2015) Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340–344. doi:10.1038/nature14547.
137. Pemberton S. et al. (2011) Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. J. Biol. Chem. 286, 34690–34699. doi:10.1074/jbc.M111.261321.
138. Perry G. et al. (1992) Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res. 579, 350–352.
139. Pieri L., Madiona K., Bousset L. and Melki R. (2012) Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys. J. 102, 2894–2905. doi:S0006-3495(12)00550-4 [pii]10.1016/j.bpj.2012.04.050.
140. Porcari R. et al. (2015) The H50Q mutation induces a 10-fold decrease in the solubility of alpha-synuclein. J. Biol. Chem. 290, 2395–2404. doi:10.1074/jbc.M114.610527.
141. Prusiner S. B. (1982) Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144. doi:10.1126/Science.6801762.
142. Prusiner S. B. (1991) Molecular biology of prion diseases. Science 252, 1515–1522.
143. Prusiner S. B. (1998) Prions. Proc. Natl Acad. Sci. USA 95, 13363–13383.
144. Prusiner S. B. (2013) Biology and genetics of prions causing neurodegeneration. Annu. Rev. Genet. 47, 601–623. doi:10.1146/annurev-genet-110711-155524.
145. Prusiner S. B. et al. (2015) Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl Acad. Sci. USA 112, E5308–E5317. doi:10.1073/pnas.1514475112.
146. Recasens A. and Dehay B. (2014) Alpha-synuclein spreading in Parkinson's disease. Front. Neuroanat. 8, 159. doi:10.3389/fnana.2014.00159.
147. Recasens A. et al. (2014) Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351–362. doi:10.1002/ana.24066.
148. Rey N. L., Petit G. H., Bousset L., Melki R. and Brundin P. (2013) Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol. 126, 555–573. doi:10.1007/s00401-013-1160-3.
149. Reyes J. F. et al. (2013) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. doi:10.1002/glia.22611.
150. Richter-Landsberg C., Gorath M., Trojanowski J. Q. and Lee V. M. (2000) Alpha-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J. Neurosci. Res. 62, 9–14.
151. Roberts R. F., Wade-Martins R. and Alegre-Abarrategui J. (2015) Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 138, 1642–1657. doi:10.1093/brain/awv040.
152. Sacino A. N. et al. (2014a) Amyloidogenic alpha-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol. 127, 645–665. doi:10.1007/s00401-014-1268-0.
153. Sacino A. N. et al. (2014b) Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl Acad. Sci. USA 111, 10732–10737. doi:10.1073/pnas.1321785111.
154. Sasaki H. et al. (2011) Copy number loss of (src homology 2 domain containing)-transforming protein 2 (SHC2) gene: discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy. Mol. Brain 4, 24–34. doi:Artn 2410.1186/1756-6606-4-24.
155. Savica R., Grossardt B. R., Bower J. H., Ahlskog J. E. and Rocca W. A. (2013) Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 70, 859–866. doi:10.1001/jamaneurol.2013.114.
156. Sawaya M. R. et al. (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447, 453–457. doi:10.1038/nature05695.
157. Schapira A. H. and Tolosa E. (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat. Rev. Neurol. 6, 309–317. doi:10.1038/nrneurol.2010.52.
158. Schrag A., Ben-Shlomo Y. and Quinn N. P. (1999) Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 354, 1771–1775. doi:10.1016/S0140-6736(99)04137-9.
159. Schulz-Schaeffer W. J. (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 120, 131–143. doi:10.1007/s00401-010-0711-0.
160. Serio T. R. et al. (2000) Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317–1321.
161. Serpell L. C., Berriman J., Jakes R., Goedert M. and Crowther R. A. (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl Acad. Sci. USA 97, 4897–4902.
162. Shrivastava A. N. et al. (2015) Alpha-synuclein assemblies sequester neuronal alpha3-Na+/K + -ATPase and impair Na+ gradient. EMBO J. 34, 2408–2423. doi:10.15252/embj.201591397.
163. Singleton A. B. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841. doi:302/5646/841 [pii]10.1126/science.1090278.
164. Solforosi L., Milani M., Mancini N., Clementi M. and Burioni R. (2013) A closer look at prion strains: characterization and important implications. Prion 7, 99–108. doi:10.4161/pri.23490.
165. Spillantini M. G. and Goedert M. (2000) The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 920, 16–27.
166. Spillantini M. G. et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839–840. doi:10.1038/42166.
167. Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998a) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469–6473.
168. Spillantini M. G. et al. (1998b) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251, 205–208.
169. Stefani M. and Dobson C. M. (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678–699. doi:10.1007/s00109-003-0464-5.
170. Steiner J. A., Angot E. and Brundin P. (2011) A deadly spread: cellular mechanisms of alpha-synuclein transfer. Cell Death Differ. 18, 1425–1433. doi:10.1038/cdd.2011.53.
171. Stuendl A. et al. (2015) Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain. doi:10.1093/brain/awv346.
172. Tanaka M., Chien P., Naber N., Cooke R. and Weissman J. S. (2004a) Conformational variations in an infectious protein determine prion strain differences. Nature 428, 323–328. doi:10.1038/nature02392.
173. Tanaka M. et al. (2004b) Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. Chem. 279, 4625–4631. doi:10.1074/jbc.M310994200.
174. Tanaka M., Collins S. R., Toyama B. H. and Weissman J. S. (2006) The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585–589. doi:10.1038/nature04922.
175. Tang F. L. et al. (2015) VPS35 in dopamine neurons is required for endosome-to-Golgi retrieval of Lamp2a, a receptor of chaperone-mediated autophagy that is critical for alpha-synuclein degradation and prevention of pathogenesis of Parkinson's disease. J. Neurosci. 35, 10613–10628. doi:10.1523/JNEUROSCI.0042-15.2015.
176. Tartaglia G. G., Pechmann S., Dobson C. M. and Vendruscolo M. (2007) Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Biochem. Sci. 32, 204–206. doi:10.1016/j.tibs.2007.03.005.
177. Teravanesyan M. D., Dagkesamanskaya A. R., Kushnirov V. V. and Smirnov V. N. (1994) The Sup35 omnipotent Suppressor gene is involved in the maintenance of the non-mendelian determinant [Psi(+)] in the yeast Saccharomyces cerevisiae. Genetics 137, 671–676.
178. Theillet F. X. et al. (2016) Structural disorder of monomeric alpha-synuclein persists in mammalian cells. Nature. doi:10.1038/nature16531.
179. Tokuda T. et al. (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766–1772. doi:WNL.0b013e3181fd613b [pii]10.1212/WNL.0b013e3181fd613b.
180. Tong J. et al. (2010) Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 133, 172–188. doi:10.1093/brain/awp282.
181. Uversky V. N., Li J. and Fink A. L. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 10737–10744. doi:10.1074/jbc.M010907200.
182. Vilar M. et al. (2008) The fold of alpha-synuclein fibrils. Proc. Natl Acad. Sci. USA 105, 8637–8642. doi:10.1073/pnas.0712179105.
183. Vilchez D., Saez I. and Dillin A. (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nat. Commun. 5, 5659. doi:10.1038/ncomms6659.
184. Visanji N. P., Brooks P. L., Hazrati L. N. and Lang A. E. (2013) The prion hypothesis in Parkinson's disease: Braak to the future. Acta Neuropathol. Commun. 1, 2. doi:2051-5960-1-2 [pii]10.1186/2051-5960-1-2.
185. Wadsworth J. D. F. et al. (2004) Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 306, 1793–1796. doi:10.1126/science.1103932.
186. Wakabayashi K. et al. (1998a) Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. 96, 445–452.
187. Wakabayashi K., Yoshimoto M., Tsuji S. and Takahashi H. (1998b) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249, 180–182. doi:10.1016/S0304-3940(98)00407-8.
188. Wang L. et al. (2014) Alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr. Biol. 24, 2319–2326. doi:10.1016/j.cub.2014.08.027.
189. Watts J. C. et al. (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc. Natl Acad. Sci. USA 110, 19555–19560. doi:10.1073/pnas.1318268110.
190. Waudby C. A. et al. (2010) The interaction of alphaB-crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation. Biophys. J. 98, 843–851. doi:10.1016/j.bpj.2009.10.056.
191. Webb J. L., Ravikumar B., Atkins J., Skepper J. N. and Rubinsztein D. C. (2003) Alpha-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009–25013. doi:10.1074/jbc.M300227200.
192. Wickner R. B. (1994) [Ure3] as an altered Ure2 protein - evidence for a prion analog in Saccharomyces cerevisiae. Science 264, 566–569. doi:10.1126/Science.7909170.
193. Wilhelm B. G. et al. (2014) Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins. Science 344, 1023–1028. doi:10.1126/science.1252884.
194. Will R. G. (2003) Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br. Med. Bull. 66, 255–265. doi:10.1093/bmb/dg66.255.
195. Will R. G. et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347, 921–925.
196. Woerman A. L. et al. (2015) Propagation of prions causing synucleinopathies in cultured cells. Proc. Natl Acad. Sci. USA 112, E4949–E4958. doi:10.1073/pnas.1513426112.
197. Wong E. S. et al. (2008) Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum. Mol. Genet. 17, 2570–2582. doi:10.1093/hmg/ddn157.
198. Xue W. F., Hellewell A. L., Hewitt E. W. and Radford S. E. (2010) Fibril fragmentation in amyloid assembly and cytotoxicity: when size matters. Prion 4, 20–25.
199. Zhu M., Li J. and Fink A. L. (2003) The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem. 278, 40186–40197. doi:10.1074/jbc.M305326200.